Ascendiant Capital Markets Forecasts NDRA Q1 Earnings

ENDRA Life Sciences Inc. (NASDAQ:NDRA) – Analysts at Ascendiant Capital Markets issued their Q1 2027 earnings per share (EPS) estimates for shares of ENDRA Life Sciences in a research report issued to clients and investors on Sunday, April 5th. Ascendiant Capital Markets analyst E. Woo expects that the company will post earnings per share of ($1.07) for the quarter. The consensus estimate for ENDRA Life Sciences’ current full-year earnings is ($47.46) per share. Ascendiant Capital Markets also issued estimates for ENDRA Life Sciences’ Q2 2027 earnings at ($1.00) EPS, Q3 2027 earnings at ($0.97) EPS, Q4 2027 earnings at ($0.97) EPS and FY2027 earnings at ($4.00) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $30.00.

ENDRA Life Sciences Stock Up 2.7%

NASDAQ NDRA opened at $5.31 on Thursday. ENDRA Life Sciences has a twelve month low of $2.90 and a twelve month high of $11.96. The company has a market cap of $3.98 million, a price-to-earnings ratio of -0.60 and a beta of -0.23. The business’s fifty day moving average is $3.88 and its 200 day moving average is $4.87.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new position in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for 0.9% of Altium Capital Management LLC’s holdings, making the stock its 17th biggest holding. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent SEC filing. Institutional investors and hedge funds own 1.19% of the company’s stock.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.